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(P 5 0.0001), gender (P 5 0.0005), and vitamin B12 levels (P 5Effect of MTHFR 677C.T on plasma total homocysteine lev-
0.004) on total homocysteine concentrations was observed. Theels in renal graft recipients.
donor MTHFR gene polymorphism had no influence on totalBackground. Hyperhomocysteinemia is an established, in-
homocysteine and folate levels. Geometric mean total homo-dependent risk factor for vascular disease morbidity and mor-
cysteine levels in patients homozygous for the mutant MTHFRtality. The 5,10-methylenetetrahydrofolate reductase (MTHFR)
allele were 18.6 mmol/liter compared with 14.6 mmol/liter andgene polymorphism C677T has been shown to result in in-
14.9 mmol/liter in patients heterozygous for the MTHFR genecreased total homocysteine concentrations on the basis of low
polymorphism and those with wild-type alleles (P , 0.05 forfolate levels caused by a decreased enzyme activity. The effect
TT vs. CT and CC). Geometric mean folate levels were lowerof this polymorphism on total homocysteine and folate plasma
in CT and TT patients (11.2 and 10.2 nmol/liter) comparedlevels in renal transplant patients is unknown.
Methods. We screened 636 kidney graft recipients for the with CC patients (13.6 nmol/liter, P , 0.05 vs. CT and TT).
presence of the MTHFR C677T gene polymorphism. The major Conclusions. This study demonstrates that homozygosity for
determinants of total homocysteine and folate plasma concen- the C677T polymorphism in the MTHFR gene significantly
trations of 63 patients, who were identified to be homozygous increases total homocysteine concentrations and lowers folate
for this gene polymorphism compared with heterozygotes (N 5 levels in kidney graft recipients, even in patients with excellent
63), and patients with wild-type alleles (N 5 63), who were renal function (GFR more than median). These findings have
matched for sex, age, glomerular filtration rate (GFR), and body important implications for risk evaluation and vitamin inter-
mass index, were identified by analysis of covariance. The vari- vention therapy in these patients who carry an increased risk
ables included sex, age, GFR, body mass index, time since for the development of cardiovascular disease.
transplantation, folate and vitamin B12 levels, the use of azathio-
prine, and the MTHFR genotype. To investigate the impact
of the kidney donor MTHFR genotype on total homocysteine
Homocysteine is a toxic intermediate product of theand folate plasma concentrations, a similar model was applied
in 111 kidney graft recipients with stable graft function, in protein catabolism and is normally removed by either
whom the kidney donor C677T MTHFR gene polymorphism transulfuration to cysteine or remethylation to methio-
was determined. nine [1]. An increased plasma concentration of totalResults. The allele frequency of the C677T polymorphism
homocysteine, referred to as hyperhomocysteinemia, rep-in the MTHFR gene was 0.313 in the whole study population
resents an important, independent risk factor for vascular[wild-type (CC), 301; heterozygous (CT), 272; and homozygous
mutant (TT), 63 patients, respectively] and showed no differ- disease and mortality in the general population [2–11]
ence in the patient subgroups with various renal diseases. The and particularly in chronic renal failure patients [12–16].
MTHFR C677T gene polymorphism significantly influenced
Homocysteine moieties in plasma are elevated at thetotal homocysteine and folate plasma concentrations in renal
incipient stage of renal failure, and any further increasetransplant recipients (P 5 0.0009 and P 5 0.0002, respectively).
Furthermore, a significant influence of the GFR (P 5 0.0001), also correlates with the decline of the glomerular filtra-
folate levels (P 5 0.0001), age (P 5 0.0001), body mass index tion rate (GFR) [17–23]. This observation suggested an
involvement of the kidney in the homocysteine metabo-
lism. Indeed, Bostom et al demonstrated a substantialKey words: hyperhomocysteinemia, transplantation, polymorphism,
MTHFR, folate, vitamin B12, cardiovascular disease. lower homocysteine content in blood of the renal vein
of rats compared with blood obtained from the renalReceived for publication October 13, 1997
artery, whereas urinary excretion was negligible [24].and in revised form August 24, 1998
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ferase [26, 27], and methionine synthetase [27], activity one was kept on prednisolone monotherapy. Routine
vitamin supplementation was not performed in thisof 5,10-methylenetetrahydrofolate reductase (MTHFR)
has also been detected in human kidneys [28]. This en- group of patients. Written informed consent was given
by all kidney graft recipients according to the declarationzyme provides 5-methyltetrahydrofolate, the active form
of folate, which is necessary as a methyl donor for re- of Helsinki and the Austrian law on gene technology.
methylation of homocysteine to methionine [1]. Healthy
Kidney donorssubjects as well as end-stage renal failure patients with
suboptimal folate intake are at risk for the development The DNA of local organ donors from the University
of Vienna Transplantation Center was collected sinceof hyperhomocysteinemia [29, 30]. In this context, sup-
plementation with folate has been shown to represent a 1993, when molecular human leukocyte antigen typing
was routinely performed. To analyze the influence of thepowerful therapeutic approach for lowering total homo-
cysteine concentrations [31–33]. kidney donor MTHFR genotype on total homocysteine
and folate plasma concentrations, 111 renal transplantRecently, a polymorphism C677T in the gene coding
for the enzyme MTHFR was identified. This polymor- patients who had received a kidney graft from local organ
donors and had serum creatinine levels of less than 2phism may result in low levels of active folate on the
basis of a decreased enzyme activity and can cause an mg/dl and a stable renal function at the time of the study
were investigated. Ninety-seven donor DNA samplesincrease of total homocysteine plasma levels [34, 35].
Furthermore, homozygosity for the mutant allele (TT) (from 14 of these donors, both kidneys were transplanted
in our center) were tested for the C677T polymorphismmay confer an increased risk for vascular disease [36–39].
The influence of the C677T MTHFR gene polymor- in the MTHFR gene.
phism on total homocysteine and folate plasma levels in
Measurementsrenal graft recipients is unknown. We tested the hypothe-
sis that a decreased MTHFR activity of the kidney recipi- Fasting citrated blood from kidney graft recipients was
immediately placed on ice and was centrifuged withinent or the kidney donor, caused by homozygosity for the
C677T transition in the MTHFR gene, elevates total 60 minutes at 2000 3 g at 48C (20 min). Plasma aliquots
were snap frozen and stored at 2708C. Citrated bloodhomocysteine and lowers folate plasma concentrations
in kidney graft recipients. was kept at 2208C for extraction of DNA. Total (5 free
plus protein-bound) plasma homocysteine concentrations
were determined by automated high-performance liquid
METHODS
chromatography with reversed-phase separation and flu-
Kidney graft recipients orescence detection using a commercially available kit
(Immundiagnostik, Bensheim, Germany) as describedA group of 636 kidney graft recipients (251 females,
385 males; age 52.0 6 13.5 years; time since transplanta- previously [40, 41]. Hyperhomocysteinemia was defined
as the total homocysteine levels above 15 mmol/liter.tion 5.7 6 4.1 years; serum creatinine 1.8 6 1.0 mg/dl;
GFR 55.3 6 20.4 ml/min; body mass index 25.4 6 4.2 Plasma folate (5-methyltetrahydrofolate) and vitamin B12
levels were measured with a radioassay that allowed simul-kg/m2; mean 6 sd) followed at the outpatient service of
the University Hospital of Vienna was screened for the taneous determination of both vitamin concentrations in
a single reaction tube (SimulTRAC-SNB; Becton Dickin-presence of the C677T MTHFR polymorphism.
To analyze the impact of the mutated MTHFR allele son, Ontario, Canada). Folate deficiency was considered
present at a plasma concentration of less than 3.4 nmol/on total homocysteine and folate concentrations, vitamin
B12, folate and total homocysteine levels were deter- liter. Vitamin B12 deficiency was defined as a concentration
of less than 118 pmol/liter, respectively. GFR was calcu-mined in all homozygous C677T MTHFR patients (N 5
63) and were compared with heterozygotes and negative lated using the equation of Cockcroft and Gault [42].
Identification of the 677 C to T transition in the MTHFRpatients, who were matched for sex, age, GFR, and body
mass index. Immunosuppressive triple therapy consisted gene was performed as previously described [34].
of cyclosporine A, corticosteroids, and azathioprine in 95
Statistical methodspatients. Mycophenolate mofetil instead of azathioprine
was used in 16 patients. Fifty-one patients received cyclo- Comparison of the frequency of the different MTHFR
alleles at nucleotide position 677 in kidney graft recipi-sporine A combined with prednisolone, and 12 patients
were maintained on monotherapy with cyclosporine A. ents (N 5 636) according to the primary kidney disease
was performed by a chi-square test. Potential differencesAzathioprine in combination with prednisolone or aza-
thioprine together with cyclosporine A was used in five of age, time since transplantation, body mass index, and
GFR in the three patient groups according to the MTHFRpatients. Tacrolimus combined with prednisolone was
used in three patients. One patient received cyclosporine C677T genotype (CC, N 5 301; CT, N 5 272; TT, N 5
63) were assessed by analysis of variance. DescriptiveA, prednisolone, and cyclophosphamide, and another
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Table 1. Allele frequencies and prevalence of the C677T MTHFR alleles according to primary kidney disease in 636 kidney graft recipients
(percentages in brackets)
MTHFR (C677T)
transition All patients DN GN PKD SK IN MIX
N 636 40 (6.3) 224 (35.2) 85 (13.4) 121 (19.0) 114 (17.9) 52 (8.2)
CC 301 (47.3) 18 (45.0) 113 (50.4) 46 (54.1) 52 (43.0) 46 (40.3) 26 (50.0)
CT 272 (42.8) 16 (40.0) 95 (42.4) 27 (31.8) 52 (43.0) 59 (51.8) 23 (44.2)
TT 63 (9.9) 6 (15.0) 16 (7.2) 12 (14.1) 17 (14.0) 9 (7.9) 3 (5.8)
Allele frequency 0.313 0.450 0.283 0.300 0.356 0.338 0.279
Abbreviations are: DN, diabetic nephropathy; GN, glomerulonephritis; PKD, polycystic kidney disease; SK, shrunken kidneys of unknown etiology; IN, interstitial
nephritis; MIX, miscellaneous nephropathies; CC, wild-type; CT, heterozygotes; TT, homozygous mutant alleles.
statistics included mean values 6 sd, geometric means, RESULTS
medians, and full ranges for continuous data and percent- MTHFR C677T gene polymorphism in kidney
age for categorical data. Pearson’s correlation was used graft recipients
to assess linear associations. Because plasma total homo-
The allele frequency of the C677T transition in thecysteine and folate measures were positively skewed,
MTHFR gene in 636 renal graft recipients was 0.313,natural logarithmic transformation was used to normalize
which is comparable with the frequencies described forthe distribution (natural logarithm of total homocysteine/
healthy individuals in Austria [40, 42]. Within the threefolate concentrations, ln-total homocysteine/ln-folate).
groups of patients who were homozygous (N 5 63, 9.9%)Separate comparisons of ln-total homocysteine plasma
or heterozygous (N 5 272, 42.8%) for the mutantlevels between the three groups of TT kidney graft recipi-
MTHFR allele or had wild-type alleles (N 5 301, 47.3%),ents with sex-, age-, GFR-, and body mass index-matched
there was no significant difference of age (54.8 6 12.6,CT and CC subjects were performed by analysis of covar-
51.7 6 13.8, 51.7 6 13.3 years, respectively), time sinceiance. The covariables were vitamin B12 and folate levels, transplantation (5.7 6 4.2, 5.9 6 4.1, 5.4 6 4.0 years,age, gender, GFR, body mass index, time since trans-
respectively), GFR (55.7 6 22.3, 55.7 6 20.5, 54.7 6 20.1plantation, and the use/nonuse of azathioprine in the
ml/min, respectively) and body mass index (25.4 6 4.0,immunosuppressive protocol. In an additional analysis,
25.5 6 4.2, 25.3 6 4.3 kg/m2, respectively). The preva-the influence of the interaction term “GFR 3 folate,”
lence of the MTHFR C677T gene polymorphism ac-together with the MTHFR genotype (CC or CT or TT),
cording to primary renal disease is indicated in Table 1.folate, and GFR on total homocysteine levels, were also
There were no differences in the frequencies of theinvestigated. Individual comparisons between the groups
MTHFR C677T genotype with regard to renal diseasewere conducted by post hoc analysis (Scheffe’s test). To
in our patients.determine which of the total homocysteine-predicting
variables enters first in a general model, a multiple step-
Influence of kidney graft recipient MTHFR C677Twise regression analysis was performed that included a
gene polymorphism on total homocysteine andTT-genotype yes/no term, folate, vitamin B12, age, sex, folate plasma concentrationsGFR, and body mass index as independent variables
Demographic data of 63 kidney graft recipients withand the total homocysteine plasma concentration as an
the MTFHR (677 TT) genotype compared with age, sex,outcome variable. The influence of the kidney graft recipi-
GFR, and body mass index matched 63 patients with CTent MTHFR genotype (CC or CT or TT) and the GFR
and 63 patients with CC genotype are given in Table 2. Weon ln-folate levels was analyzed by analysis of covariance.
observed a significant influence of the recipient MTHFRThe impact of the kidney donor MTHFR genotype on
genotype, folate, GFR, vitamin B12, age, sex, and bodyln-total homocysteine plasma concentrations of kidney
mass index on total homocysteine concentrations in thesegraft recipients (N 5 111) was calculated by analysis of
189 patients, whereas time since transplantation and aza-covariance, including folate, B12, age, sex, body mass
thioprine were without any effect (Table 3). Post hocindex, GFR, time since transplantation, and an azathio-
analysis revealed that there was a significant differenceprine yes/no term. In a second model, the influence of
of total homocysteine concentrations in TT patients com-the kidney donor MTHFR genotype (CC or CT or TT)
pared with CT (P , 0.05) and CC subjects (P , 0.05;and GFR on plasma ln-folate levels was analyzed. Indi-
Fig. 1).vidual comparisons between the groups were conducted
We also observed a significant influence of theby post hoc analysis (Scheffe’s test). All calculations
MTHFR genotype (P 5 0.0002) and the GFR (P 5were performed by the statistical software package SAS
(SAS Institute Inc., Cary NC, USA). 0.013) on folate levels in kidney graft recipients. Post hoc
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Table 2. Characteristics of 63 kidney graft recipients sharing
homozygosity for the C677T transition in the MTHFR gene (TT)
compared with heterozygous patients (CT) and subjects with
wild-type alleles (CC)
MTHFR (C677T)
gene polymorphism CC CT TT
N 63 63 63
Sex female/male 29/34 29/34 29/34
Age years 54.6612.3 55.0611.8 54.8612.6
Transplanted years 5.464.0 6.063.8 5.764.2
Body mass index kg/m2 25.964.0 25.863.7 25.464.0
Serum creatinine mg/dl 1.861.2 1.660.8 1.861.4
GFR ml/min 55.2620.3 56.1620.3 55.7622.3
The patients among each group were matched for sex, age, GFR and body
mass index. Data are given as means 6 sd.
Table 3. Influence of the kidney graft recipient MTHFR C677T
gene polymorphism and other variables on total homocysteine plasma
concentrations in 189 kidney graft recipients
(analysis of covariance)
P Estimates
MTHFR (C677T) genotype 0.0009 CC: 20.17762
CT: 20.20495
TT: 0.00000
Fig. 1. Nonadjusted mean total homocysteine (h; mmol/liter) and fo-Plasma folate level 0.0001 20.01690
late (j; nmol/liter) plasma concentrations in kidney graft recipientsGFR 0.0001 20.01148
matched for sex, age, glomerular filtration rate (GFR), and body massAge 0.0001 20.00869
index with respect to the C677T MTHFR gene polymorphism (63 pa-Body mass index 0.0001 0.03337
tients in each genotype group). Whiskers denote 6sd. *P , 0.05 forSex 0.0005 0.17555
plasma folate levels of the wild-type (CC) vs. heterozygous (CT) andPlasma vitamin B12 level 0.0040 20.00045
homozygous mutant (TT) genotype patients; **P , 0.05 for total homo-Time since transplantation 0.5220 20.00384
cysteine concentrations of TT vs. CT and CC patients.Azathioprine 0.7933 0.01311
Total homocysteine, folate, and vitamin B12
plasma concentrationsanalysis demonstrated that CC patients had significantly
The plasma levels of total homocysteine, folate, andhigher folate levels compared with CT (P , 0.5) and TT
vitamin B12 of the 189 patients according to the MTHFR(P , 0.5) patients. There was no difference in folate
C677T genotype are indicated in Table 5. The prevalencelevels between CT and TT patients (Fig. 1).
of moderate or intermediate hyperhomocysteinemia asThere was no linear association of the GFR with folate
well as the absence of hyperhomocysteinemia is indi-levels (r 5 20.077, P 5 0.29). However, inclusion of a
cated in Table 6. Out of 189 patients, 1 patient with a“GFR 3 folate” interaction term revealed a significant
TT genotype presented with subnormal folate levels,influence on total homocysteine levels (P 5 0.0002). In
whereas 11 patients had subnormal vitamin B12 levelsthis analysis, the influence of MTHFR increased (P 5
(TT, 7; CT, 2; CC, 2 patients, respectively).
0.0001), and the influence of folate on total homocysteine
Even patients with excellent graft function (GFR more
levels decreased (P 5 0.0193), whereas the influence of than the sample median) with the homozygous MTHFR
the GFR alone was not greater (P 5 0.3). The relation- C677T gene polymorphism had higher total homocys-
ship of the GFR with total homocysteine levels according teine concentrations than heterozygotes and patients
to the MTHFR C677T polymorphism is indicated in Fig- without polymorphism (Fig. 3).
ure 2.
Multiple stepwise regression analysis including a Influence of kidney donor MTHFR C677T gene
polymorphism on total homocysteine and folateMTHFR (677 TT) genotype yes/no term, folate and vita-
plasma concentrationsmin B12 levels, GFR, body mass index, sex and age as
independent variables, and plasma total homocysteine The MTHFR C677T polymorphism was determined
concentration as outcome variable confirmed the clear in 111 kidneys obtained from 97 organ donors (CC, 50;
influence of the MTHFR (TT) genotype on total homo- CT, 45; TT, 16 donor kidneys, respectively). A TT kidney
was implanted in six CC, eight CT, and two TT patients.cysteine concentrations (Table 4).
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Fig. 2. Nonadjusted total homocysteine (tHcy)
plasma concentrations according to the glo-
merular filtration rate (GFR) in the three
groups of kidney graft recipients with (A) wild-
type (CC), (B) heterozygous (CT), and (C )
homozygous mutant (TT) MTHFR alleles.
Kidneys with the CT genotype were transplanted into 3 recipients (N 5 111). In this patient group, folate (P 5
0.045), age (P 5 0.037), body mass index (P 5 0.005),TT, 14 CT, and 28 CC kidney graft recipients. Nine,
13, and 28 patients with the TT, CT, and CC genotype and GFR (P 5 0.0005) had a significant influence on
total homocysteine concentrations, whereas vitamin B12received donor kidneys without the C677T transition in
the MTHFR gene. levels, gender, azathioprine, and time since transplanta-
tion showed no effect. Furthermore, the donor MTHFRIn contrast to the recipient MTHFR genotypes, the
donor MTHFR gene polymorphism had no influence gene polymorphism (P 5 0.33) and the GFR (P 5 0.71)
showed no effect on folate levels in these patients.on total homocysteine concentrations in kidney graft
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Table 4. Multiple stepwise regression analysis of major
determinants of hyperhomocysteinemia in 189 kidney
graft recipients according to the order the variables
entered in the stepwise procedure
P
1. Glomerular filtration rate 0.0001
2. Plasma folate level 0.0001
3. MTHFR (TT) genotype 0.0005
4. Sex 0.0005
5. Body mass index 0.0007
6. Age 0.0001
7. Plasma vitamin B12 level 0.0016
Table 5. Total homocysteine, folate and vitamin B12 plasma levels
in 189 kidney graft recipients according to the MTHFR
C677T alleles (TT, CT or CC genotype)
MTHFR C677T Geometric
alleles N Mean 6 sd mean Median Range
Total homocysteine
plasma levels
lmol /liter
TT 63 21.0612.3 18.6 19.9 85.4
CT 63 15.767.0 14.6 14.0 41.1
CC 63 16.066.4 14.9 14.3 29.3
Total 189 17.669.2 15.9 15.1 85.8
Fig. 3. Mean total homocysteine (tHcy) concentrations in patients withFolate plasma levels
a glomerular filtration rate (GFR) . the whole sample median (j) andnmol /liter
in patients with GFR # the sample median (h) according to theTT 63 11.467.6 10.2 9.6 56.7
MTHFR C677T gene polymorphism (63 patients in each genotypeCT 63 12.064.6 11.2 12.0 24.6
group). *P , 0.05 for plasma total homocysteine concentrations of TTCC 63 14.465.1 13.6 13.9 25.2
vs. CT and CC patients with GFR # sample median; **P , 0.05 forTotal 189 12.666.0 11.6 11.7 56.7
plasma total homocysteine concentrations of TT vs. CT and CC patientsVitamin B12 plasma
with a GFR more than sample median.levels pmol /liter
TT 63 232.46107.1 208.8 199.9 458.5
CT 63 305.06216.8 268.9 276.5 1627.5
CC 63 263.16118.7 240.0 237.3 587.4
Total 189 266.86157.6 237.9 237.3 1675.8
within the subgroups of patients with various primary
renal diseases. Because there was no significant differ-
ence in time since transplantation and in the GFR be-
Table 6. Prevalence of no, moderate and intermediate tween the three genotype groups among the entire study
hyperhomocysteinemia in 189 kidney graft recipients according to
population, the MTHFR polymorphism does not appearMTHFR C677T gene polymorphisms (percentages are in brackets)
to be related to transplant dysfunction in our patients.
tHcy plasma
Wilcken, Gupta and Betts were the first to describeconcentration
lmol /liter ,15 15–30 30–100 elevated homocysteine levels in kidney graft recipients
with stable graft function [43]. HyperhomocysteinemiaTT 21 (33.3) 34 (54.0) 8 (12.7)
CT 37 (58.7) 24 (38.1) 2 (3.2) has also been shown to correlate inversely with the GFR
CC 34 (54.0) 26 (41.3) 3 (4.7) in kidney graft recipients [44] and was found to be associ-
Abbreviations are in Table 1; tHcy is total homocysteine. ated with vascular disease in these patients [44, 45]. In
these studies, older and male patients presented with
higher total homocysteine levels than younger subjects
DISCUSSION and females [44, 45]. An influence of immunosuppressive
therapy on total homocysteine levels has been discussedHomozygosity for the common C677T polymorphism
controversially [44, 46]. In this context, cyclosporine Ain the MTHFR gene increases total homocysteine plasma
was suspected to result in elevated total homocysteineconcentrations and lowers plasma folate levels in kidney
levels [44]. In our study, however, we observed no effectgraft recipients, whereas the donor MTHFR genotype
of azathioprine on homocysteine metabolism. Most re-has no major impact on hyperhomocysteinemia and fo-
cently, Bostom et al demonstrated an increased preva-late status in these patients. The allelic frequency of this
lence of post-methionine loading hyperhomocysteinemiapolymorphism in kidney graft recipients is comparable
with healthy individuals and shows the same behavior in renal transplant patients, which points to the possibil-
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ity of an impaired trans-sulfuration pathway in these more than the sample median as compared with patients
with GFR less than the sample median. There was alsopatients [47]. Also notable is that hyperhomocysteinemia
in kidney graft recipients has been shown to be partially an influence of gender, age, and body mass index on
total homocysteine concentrations (estimated increase ofcorrectable by folate, vitamin B6, or vitamin B12 interven-
tion [48, 49]. ln-total homocysteine male vs. female, 0.176; estimated
increase of ln-total homocysteine per 10 years of age,The enzyme methylenetetrahydrofolate-homocysteine
methyltransferase remethylates homocysteine to methi- 0.087; estimated increase of ln-total homocysteine per
increase of body mass index for one unit, 0.033), whichonine [1]. This metabolic pathway requires the enzyme
MTHFR for conversion of 5,10-methylenetetrahydrofo- is in contrast to dialysis patients, in whom no influence
of sex and age was observed in previous studies [40, 41].late to 5-methyltetrahydrofolate, the active form of fo-
late, which is also present in human kidneys [28]. The There was also a significant influence of the recipient
MTHFR C677T genotype on plasma folate concentra-reaction provides the methyl group for methionine syn-
thesis from homocysteine by methyl-cobalamin. A de- tions in our patients. Subjects with one or two mutated
alleles had significantly lower plasma folate levels com-creased MTHFR activity caused by mutated MTHFR
alleles may result in increased total homocysteine con- pared with patients with wild-type alleles (Fig. 1). This
finding corresponds to the study of Molloy et al, whocentrations in renal failure patients because of a further
impairment of methylation processes by low folate levels. described a significant influence of the 677 C to T transi-
tion on red cell folate and plasma folate levels in preg-Indeed, recent studies demonstrated the presence of
higher total homocysteine concentrations in end-stage nant and nonpregnant women [35]. Thus, patients who
are homozygous for the MTHFR 677 C to T polymor-renal disease patients treated with dialysis with this poly-
morphism [40, 41]. phism may have a better response to nutritional folate
supply [33].This study clearly demonstrates that homozygosity for
the C677T transition in the MTHFR gene of the graft With respect to the donor C677T MTHFR genotype,
we did not observe either an influence on plasma totalrecipient results in a further increase of total homocys-
teine levels in kidney transplant patients, whereas the homocysteine levels or on folate levels, although there
was a tendency to lower folate levels in patients whodonor genotype is without effect. More precisely, the
mean total homocysteine concentration in TT patients received a TT kidney graft. It is possible that intracellular
folate in these patients might be significantly reduced,was 21.0 6 12.3 mmol/liter versus 15.7 6 7.0 and 16.0 6
6.4 mmol/liter in CT and CC patients (estimated increase because red cell folate levels have been shown to be
decreased in subjects with the homozygous C677Tof ln-total homocysteine is 0.205 vs. CT and 0.178 vs.
CC patients), who were matched for sex, age, GFR, and MTHFR gene polymorphism [35]. Nevertheless, our re-
sults suggest that the remethylation pathway of homocys-body mass index (Fig. 1). This finding is in line with other
studies in subjects on renal replacement therapy under- teine conversion in the human kidney is of minor impor-
tance, although kidney tissue is enriched with folate andgoing either hemodialysis or peritoneal dialysis therapy
[40, 41], and supports the importance for vitamin inter- also expresses MTHFR activity [28].
An excess cardiovascular disease morbidity and mor-vention therapy in these patients [31, 32, 48, 49] because
folate and vitamin B12 also had a significant influence on tality, which is mainly due to hypertension, glucose intol-
erance, and hyperlipidemia, are commonly observed inhyperhomocysteinemia in our study (estimated increase
of ln-total homocysteine per 10 nmol/liter decrease of kidney transplant patients [50]. In this context, hyperho-
mocysteinemia has been described as an additional cardio-folate, 0.169; estimated increase of ln-total homocysteine
per 100 pmol/liter decrease of vitamin B12, 0.045). Ex- vascular risk factor in these patients [44, 45]. We demon-
strate here that markedly elevated total homocysteinepectedly, there was also a significant influence of the
GFR, as measured by a stepwise analysis, on plasma plasma concentrations are present even in renal trans-
plant patients with excellent graft function who are ho-total homocysteine and folate levels in the kidney graft
recipients (estimated increase of ln-total homocysteine mozygous for the C677T polymorphism of the MTHFR
gene. In contrast, most of the patients with excellentper 10 ml/min decrease of GFR 5 0.115). One can argue
that the interaction of the GFR with folate levels might graft function who were heterozygous or homozygous
for the wild-type allele had total homocysteine levelsalso have an important influence on total homocysteine
concentrations in this patient population. However, there within the normal range (Fig. 3). In context with a recent
comment by Nath, our observation explains the presencewas no linear association of folate levels with the GFR,
and the impact of the MTHFR genotype on homocysteine of hyperhomocysteinemia in a significant subset of kid-
ney graft recipients in whom the cardiovascular risk per-levels remained stable after adjustment for a “GFR 3
folate” interaction term in our analysis. Of utmost impor- sists even in the presence of excellent renal function [51].
In summary, we report here that the C677T polymor-tance, the behavior of plasma total homocysteine con-
centrations in TT patients was similar in those with GFR phism in the gene coding for the enzyme MTHFR ele-
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risk of atherosclerosis in end-stage renal disease and is closelyvates plasma total homocysteine and lowers plasma fo-
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